WO2009025398A1 - Solution de décellularisation, procédé de préparation d'un tissu décellularisé, greffe et élément de culture - Google Patents

Solution de décellularisation, procédé de préparation d'un tissu décellularisé, greffe et élément de culture Download PDF

Info

Publication number
WO2009025398A1
WO2009025398A1 PCT/JP2008/065475 JP2008065475W WO2009025398A1 WO 2009025398 A1 WO2009025398 A1 WO 2009025398A1 JP 2008065475 W JP2008065475 W JP 2008065475W WO 2009025398 A1 WO2009025398 A1 WO 2009025398A1
Authority
WO
WIPO (PCT)
Prior art keywords
serum
tissue
decellularized
treatment solution
graft
Prior art date
Application number
PCT/JP2008/065475
Other languages
English (en)
Japanese (ja)
Inventor
Akio Kishida
Toshiya Fujisato
Tsuyoshi Kimura
Seiichi Funamoto
Original Assignee
National University Corporation, Tokyo Medical And Dental University
Josho Gakuen Educational Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation, Tokyo Medical And Dental University, Josho Gakuen Educational Foundation filed Critical National University Corporation, Tokyo Medical And Dental University
Publication of WO2009025398A1 publication Critical patent/WO2009025398A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • Decellularized treatment solution decellularized tissue preparation method, graft, and culture member
  • the present invention relates to a decellularized treatment solution for decellularizing an original tissue derived from an animal, a method for preparing a decellularized tissue using the decellularized treatment solution, and a graft and a culture comprising the decellularized tissue. It relates to members.
  • a technique has recently been developed in which a decellularized tissue, which is a supporting tissue that remains after removing cells from a living tissue that improves compatibility with the living tissue, is used as a graft.
  • Removal of cellular components, that is, decellularization is generally performed by washing the original tissue with a treatment solution containing a surfactant.
  • Patent Document 1 Japanese Translation of Special Publication 2005—514971
  • Patent Document 2 Japanese Translation of Special Publication 2006—507851
  • the present invention has been made in view of the above circumstances, and a decellularization treatment solution that can improve safety and production efficiency and can be sufficiently decellularized, and decellularization using the decellularization treatment solution. It is an object of the present invention to provide a tissue preparation method, and a graft and a culture member provided with the decellularized tissue.
  • the present inventors have found that serum or serum derivatives have excellent permeability and decellularization ability, and have completed the present invention. Specifically, the present invention provides the following.
  • a decellularized treatment solution containing animal-derived serum or serum derivative as an active ingredient containing animal-derived serum or serum derivative as an active ingredient.
  • serum or serum derivative since serum or serum derivative is used as an active ingredient, the original tissue is rapidly and sufficiently decellularized.
  • serum or serum derivatives are derived from animals, they are more biocompatible than human compounds. For this reason, even if it is not necessary to wash serum or serum derivatives, it takes a short time.
  • the production efficiency and safety of the graft can be greatly improved and sufficient decellularization can be achieved.
  • serum or serum derivative as an active ingredient means any ingredient other than serum or serum derivative, as long as safety, production efficiency, and decellularization ability are not inhibited beyond an acceptable range. It may be contained.
  • serum derivative refers to a serum that has been treated so that safety, production efficiency, and decellularization ability are not inhibited beyond acceptable limits.
  • the ultrahigh hydrostatic pressure is set to 1000 atmospheres or more, the resident bacteria are sufficiently destroyed, and the resident bacteria remain in the decellularized tissue. Therefore, safety can be further improved.
  • a graft comprising a decellularized tissue prepared by the preparation method described above.
  • a decellularized tissue prepared by the preparation method according to (5) comprising: A culture member used for culturing cells of an adjacent tissue adjacent to the original tissue.
  • the original tissue is rapidly and sufficiently decellularized.
  • serum or serum derivatives are derived from animals, they have higher biocompatibility than artificial compounds. For this reason, even if it is not necessary to wash the serum or serum derivative, it takes a short time. Therefore, the production efficiency and safety of the graft can be greatly improved and sufficient decellularization can be achieved.
  • FIG. 1 is a view showing a usage state of a decellularized treatment solution according to an example of the present invention.
  • FIG. 2 is a view showing a state of decellularization of the original tissue when a decellularization treatment solution according to an example of the present invention is used.
  • FIG. 3 is a view showing a state of decellularization of another original tissue when the decellularization treatment solution according to the example of the present invention is used.
  • the decellularized treatment solution contains animal-derived serum or serum derivative as an active ingredient.
  • the animal from which the serum is derived is not particularly limited, and examples thereof include humans, rabbits, and pigs.
  • human-derived serum is preferable in that an inflammatory reaction caused by complement or the like can be suppressed.
  • a serum derivative refers to a product obtained by subjecting serum to a treatment that does not inhibit the safety, production efficiency, and decellularization ability beyond an acceptable range.
  • a treatment include, but are not limited to, deactivation, application of ultrahigh hydrostatic pressure, dilution, and the like.
  • high-temperature and high-pressure sterilization such as autoclave and irradiation with 0-ray for a long time are not applicable to the above treatment.
  • Inactivation can be achieved by heating to inactivate complement by heating, usually at about 56 ° C for about 30 minutes. By deactivating, inflammation after transplantation is suppressed, so safety can be further improved.
  • the application of ultra-high hydrostatic pressure is a process that destroys cells, resident bacteria, and viruses in the original tissue by applying ultra-high hydrostatic pressure to serum in a liquid.
  • the intensive treatment ensures a very high level of safety, so that serum after an inappropriate period of time can be used for transfusion applications. Since such serum can be obtained at low cost, the manufacturing cost of the graft can be reduced while maintaining safety.
  • the ultra-high hydrostatic pressure refers to a hydrostatic pressure that can destroy normal bacteria present in serum, and specifically, it is preferably 1000 atm or higher.
  • the ultrahigh hydrostatic pressure is 4,000 atmospheres or more, for example, 10,000 atmospheres, in that it can sufficiently destroy viruses more preferably 4000 atmospheres or more in terms of sufficiently destroying bacteria present in serum. Is more preferable.
  • serum is filled in a bag of a water-impermeable film. Then, the bag is tightly sealed while taking care not to leave any gas inside. This bag is placed in the liquid in the chamber of the ultra-high hydrostatic pressure treatment device (eg “Dr. CHEF (model)” (Kobe Steel)) and the device is operated.
  • the ultra-high hydrostatic pressure treatment device eg “Dr. CHEF (model)” (Kobe Steel)
  • the application time is not particularly limited as long as a desired cell destructive property can be obtained, but it may usually be about 10 to 30 minutes.
  • the melting point of serum at a preset ultrahigh hydrostatic pressure value is calculated. Then, the ultra-high hydrostatic pressure processing device may be controlled so that the temperature in the chamber is equal to or higher than the calculated melting point.
  • the serum temperature may be fixed at a fixed value, or may be varied within the range above the melting point of the serum.
  • the serum melting pressure is calculated in advance, and in particular, the rapid change in serum temperature is suppressed by reducing the applied pressure increase and ⁇ or pressure decrease rate to a predetermined value or less. As a result, coagulation of serum during the process of pressurization and hypotension is suppressed, and a decrease in serum characteristics can be further suppressed.
  • Dilution is performed with water or buffer. Since serum (especially human serum) is expensive, the cost of producing a graft can be reduced by using a serum derivative in which serum is diluted.
  • the buffer solution is not particularly limited, and a conventionally known buffer solution such as a PBS aqueous solution, a HEPES buffer solution, or a MES buffer solution can be used.
  • the dilution ratio may be appropriately set so that the cell can be decellularized within an allowable time in accordance with the thickness, characteristics, and the like of the original tissue to be decellularized.
  • the dilution ratio may be appropriately set so that the cell can be decellularized within an allowable time in accordance with the thickness, characteristics, and the like of the original tissue to be decellularized.
  • soft tissues such as pericardium, amniotic membrane, and skin
  • the serum concentration should be from 2 to 10% by mass.
  • the serum concentration is 20%. What is necessary is just to dilute so that it may become the mass%.
  • the above decellularized treatment solution is used for the preparation of decellularized tissue. Specifically, the original tissue is impregnated in a decellularization treatment solution. The decellularized solution rapidly penetrates into the original tissue, destroys cells in the original tissue, and dissolves cell components. By convection or circulation of the decellularized treatment solution, removal of cell debris is promoted, and an immune reaction caused by the remaining debris can be suppressed. Further, a step of washing with beak water or a buffer solution that promotes removal of cell debris may be further provided.
  • the original tissue is not particularly limited, and examples thereof include soft tissues such as pericardium, amniotic membrane, and skin, moderate soft tissues such as blood vessels and cartilage, bulky tissues such as myocardium, and bones. Hard tissue.
  • the impregnation time may be set as appropriate according to the combination of the raw tissue and the decellularization solution used.
  • the raw tissue may or may not be an ultrahigh hydrostatic pressure applied in a liquid.
  • the original tissue to which no ultra-high hydrostatic pressure is applied may be sufficiently decellularized using the decellularization treatment solution of the present invention.
  • the application of ultra-high hydrostatic pressure is thought to be effective in removing abnormal prions and retroviruses mixed in the original tissue.
  • the preservation method of the decellularized tissue thus prepared is not particularly limited as long as it is sterilized, and may be frozen, wet in liquid, or dried. It is an advantage of the decellularized tissue of the present invention that the preservation method is not limited.
  • the decellularized tissue thus prepared is useful as a component of a graft to be transplanted into an animal.
  • the graft of the present invention comprises the aforementioned decellularized tissue.
  • the graft may include an adjacent tissue on the decellularized tissue in which the original tissue from which the decellularized tissue is derived is adjacent in the animal body.
  • the adjacent tissue is the corneal epithelium or corneal endothelium.
  • the decellularized tissue of the present invention is also useful as a culture material used for culturing cells of adjacent tissues. That is, the culture member of the present invention comprises the decellularized tissue described above, and cells derived from adjacent tissues are placed on the decellularized tissue under appropriate conditions. By culturing, cell culture can be performed without using a special apparatus and suppressing infection.
  • Pig-derived aorta was purchased from an edible pig farm and transported at 4 ° C. The aorta was cut into lcm pieces and wetted in a polyethylene film bag filled with PBS solution. This bag was placed in a chamber of “Dr. CHEF” (manufactured by Tohko), and a hydrostatic pressure of 6000 atmospheres was applied for 10 minutes while maintaining the temperature at 25 ° C. During this time, "Dr. CHEFJ was controlled so that the pressure increase and pressure decrease speeds were 2000 atm. Z. The aorta (original tissue) after application was removed by a clean operation, and the decellularization solution shown in A to D below. (Refer to Fig. 1.) As shown in Fig. 1, only treatment liquid D was cloudy.
  • Treatment liquid A 100% FBS
  • Treatment liquid B Supernatant obtained by applying ultrahigh hydrostatic pressure of 10,000 atm at 10 ° C for 10 minutes to 100% FBS and then centrifuging at 3500 rpm for 10 minutes
  • Treatment solution C Supernatant obtained by heating 100% FBS at 56 ° C for 30 minutes and then centrifuging at 3500 rpm for 10 minutes
  • Treatment solution D Supernatant obtained by sterilizing 100% FBS at 121 ° C and 2 atm with high-temperature steam and centrifuging at 3500i: pm for 10 minutes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention vise à proposer une solution de décellularisation, ce par quoi une décellularisation peut être conduite de manière suffisante tout en améliorant la sécurité et le rendement de production, etc. L'invention porte sur une solution de décellularisation pour décellulariser un tissu de départ provenant d'un animal qui comprend un sérum ou un dérivé de sérum d'origine animale en tant qu'ingrédient actif. En tant que dérivé de sérum, un sérum immobilisant ou un sérum ayant été traité sous ultra-haute pression hydrostatique dans un liquide est préféré. Un tissu décellularisé est préparé par immersion d'un tissu de départ dans la solution de décellularisation telle que décrite ci-dessus.
PCT/JP2008/065475 2007-08-23 2008-08-22 Solution de décellularisation, procédé de préparation d'un tissu décellularisé, greffe et élément de culture WO2009025398A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007217099A JP2009050297A (ja) 2007-08-23 2007-08-23 脱細胞処理液、脱細胞化組織の調製方法、移植片、及び培養部材
JP2007-217099 2007-08-23

Publications (1)

Publication Number Publication Date
WO2009025398A1 true WO2009025398A1 (fr) 2009-02-26

Family

ID=40378290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065475 WO2009025398A1 (fr) 2007-08-23 2008-08-22 Solution de décellularisation, procédé de préparation d'un tissu décellularisé, greffe et élément de culture

Country Status (2)

Country Link
JP (1) JP2009050297A (fr)
WO (1) WO2009025398A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539918C1 (ru) * 2013-11-29 2015-01-27 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ получения тканеспецифического матрикса для тканевой инженерии паренхиматозного органа
US9615947B2 (en) 2013-01-08 2017-04-11 The Chemo-Sero-Therapeutic Research Institute Artificial blood vessel using decellularized blood vessel sheet
US9999707B2 (en) 2014-03-04 2018-06-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method for decellularization of tissue
US11033661B2 (en) 2015-03-12 2021-06-15 Adeka Corporation Anti-adhesion material and substitute biomembrane using decellularized tissue
CN115554472A (zh) * 2022-09-22 2023-01-03 舩本诚一 一种用于移植的生物组织处理方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369945B1 (es) * 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.
WO2014181886A1 (fr) 2013-05-07 2014-11-13 一般財団法人化学及血清療法研究所 Gel hybride contenant un tissu décellularisé particulaire
KR20200016226A (ko) 2017-05-30 2020-02-14 가부시키가이샤 아데카 이식용 탈세포화 재료의 제조 방법 및 당해 재료를 포함하는 생체 적합성 재료로 이루어지는 이식편 조성물
WO2021020576A1 (fr) 2019-08-01 2021-02-04 Ｋｍバイオロジクス株式会社 Inhibiteur de fibrose tissulaire dans lequel un polymère biocompatible est utilisé

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003093A1 (fr) * 1994-07-28 1996-02-08 Ivan Vesely Implants bioprothetiques et leur procede de fabrication et d'utilisation
WO1996032905A1 (fr) * 1995-04-19 1996-10-24 St. Jude Medical, Inc. Substrat matriciel destine a une prothese derivee d'un tissu biologique vivant et son procede de fabrication
JPH09510108A (ja) * 1994-03-14 1997-10-14 クリオライフ，インコーポレイティド 移植用処理組織及び調製方法
JP2001505044A (ja) * 1996-07-31 2001-04-17 セント ジュード メディカル，インコーポレイテッド 生物プロテーゼ組織を処理するための微生物の使用
WO2002096476A1 (fr) * 2001-05-24 2002-12-05 University Of Leeds Decellularisation de matrices
JP2003518981A (ja) * 1999-12-29 2003-06-17 チルドレンズ メディカル センター コーポレーション 臓器脱細胞化のための方法および組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510108A (ja) * 1994-03-14 1997-10-14 クリオライフ，インコーポレイティド 移植用処理組織及び調製方法
WO1996003093A1 (fr) * 1994-07-28 1996-02-08 Ivan Vesely Implants bioprothetiques et leur procede de fabrication et d'utilisation
WO1996032905A1 (fr) * 1995-04-19 1996-10-24 St. Jude Medical, Inc. Substrat matriciel destine a une prothese derivee d'un tissu biologique vivant et son procede de fabrication
JP2001505044A (ja) * 1996-07-31 2001-04-17 セント ジュード メディカル，インコーポレイテッド 生物プロテーゼ組織を処理するための微生物の使用
JP2003518981A (ja) * 1999-12-29 2003-06-17 チルドレンズ メディカル センター コーポレーション 臓器脱細胞化のための方法および組成物
WO2002096476A1 (fr) * 2001-05-24 2002-12-05 University Of Leeds Decellularisation de matrices

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9615947B2 (en) 2013-01-08 2017-04-11 The Chemo-Sero-Therapeutic Research Institute Artificial blood vessel using decellularized blood vessel sheet
RU2539918C1 (ru) * 2013-11-29 2015-01-27 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ получения тканеспецифического матрикса для тканевой инженерии паренхиматозного органа
US9999707B2 (en) 2014-03-04 2018-06-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method for decellularization of tissue
US11185611B2 (en) 2014-03-04 2021-11-30 University of Pittsburgh—of the Commonwealth System of Higher Education Method and apparatus for decellularization of tissue
US11033661B2 (en) 2015-03-12 2021-06-15 Adeka Corporation Anti-adhesion material and substitute biomembrane using decellularized tissue
CN115554472A (zh) * 2022-09-22 2023-01-03 舩本诚一 一种用于移植的生物组织处理方法
CN115554472B (zh) * 2022-09-22 2023-08-18 舩本诚一 一种用于移植的生物组织处理方法
WO2024061024A1 (fr) * 2022-09-22 2024-03-28 舩本诚一 Méthode de traitement de tissu biologique pour transplantation

Also Published As

Publication number Publication date
JP2009050297A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009025398A1 (fr) Solution de décellularisation, procédé de préparation d'un tissu décellularisé, greffe et élément de culture
US11883437B2 (en) Xenograft soft tissue implants and methods of making
AU2002309898B2 (en) EB matrix production from fetal tissues and its use for tissue repair
CA2407439C (fr) Prothese individuelle de valvule du sinus veineux
US5558875A (en) Method of preparing collagenous tissue
JP6244031B2 (ja) 無細胞コラーゲン組織及び無細胞コラーゲン組織を含む人工弁膜の処理方法
AU2002309898A1 (en) EB matrix production from fetal tissues and its use for tissue repair
AU2002364511A1 (en) Eb matrix production from animal tissue and its use for tissue repair
JP2004502499A (ja) 動物の角膜組織を含むバイオマテリアル
WO2007070301A9 (fr) Stérilisation et décellularisation de greffe vasculaire
Keane et al. Decellularization of mammalian tissues: preparing extracellular matrix bioscaffolds
Duarte et al. Contributions of supercritical fluid technology for advancing decellularization and postprocessing of viable biological materials
US6933103B1 (en) Biocompatible tissue for therapeutic use and method of making same
Das et al. Tissue-derived decellularized extracellular matrices toward cartilage repair and regeneration
EP3952936A1 (fr) Procédé de prévention de la dégradation et de la dégénérescence du tissu utilisé dans une bioprothèse
Deepak et al. A review of current approaches for decellularization, sterilization, and hemocompatibility testing on xenogeneic pericardium
WO2015027728A1 (fr) Procédé pour désinfecter et stériliser une substance tissulaire d'origine animale et solution de trempage pour tissu d'origine animale correspondante
JP4861326B2 (ja) 埋め込み可能または移植可能な生体材料の製造のための滅菌方法
WO2007084798A2 (fr) Materiau de greffe tissulaire biocompatible destine a etre implante et son procede de fabrication
RU2741224C1 (ru) Способ обработки биологической ткани для имплантируемого биопротеза
EP1414368B1 (fr) Elaboration de matrice dite "eb" a partir de tissu foetal, et utilisation pour la reparation des tissus
CN117547652A (zh) 一种天然胶原蛋白基质材料脱细胞方法
Satish et al. 360 in making acellular and biocompatible xenografts for surgical applications
KR20160127077A (ko) 동물 및 특히 돼지 연골 조직의 보존 저장 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827644

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827644

Country of ref document: EP

Kind code of ref document: A1